Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.

Jasper Ridge Partners L.P. lessened its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 59.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,809 shares of the company’s stock after selling 8,559 shares during the quarter. Jasper Ridge Partners L.P.’s holdings in Revolution Medicines were worth $1,088,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Alphabet Inc. purchased a new position in Revolution Medicines during the second quarter valued at $551,843,000. Norges Bank purchased a new stake in shares of Revolution Medicines during the fourth quarter worth about $195,568,000. Avoro Capital Advisors LLC purchased a new stake in shares of Revolution Medicines during the fourth quarter worth about $172,840,000. Polar Capital Holdings Plc raised its position in shares of Revolution Medicines by 321.2% during the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after purchasing an additional 1,535,686 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Revolution Medicines by 197.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,205,555 shares of the company’s stock worth $175,672,000 after purchasing an additional 1,463,155 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $207.88 on Friday. The firm has a 50-day simple moving average of $193.33 and a 200-day simple moving average of $148.59. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. Revolution Medicines, Inc. has a 52 week low of $37.56 and a 52 week high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the business posted ($1.31) EPS. On average, equities analysts predict that Revolution Medicines, Inc. will post -8.85 earnings per share for the current fiscal year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RVMD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. Royal Bank Of Canada boosted their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a research note on Thursday. Truist Financial increased their target price on Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a report on Thursday. Sanford C. Bernstein raised their target price on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Finally, Guggenheim lifted their price target on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $198.89.

Insiders Place Their Bets

In other news, insider Stephen Michael Kelsey sold 4,175 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the transaction, the insider directly owned 291,876 shares in the company, valued at $45,567,681.12. The trade was a 1.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $160.17, for a total value of $9,674,268.00. Following the transaction, the chief operating officer owned 158,222 shares in the company, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.